[ad_1] - Major milestone for accelerating the development of HpVac-13 in allergic diseases Geneva, Switzerland, October 18, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against allergic and inflammatory diseases, today announced new data on its lead compound HpVac-13 for the treatment and prevention of asthmatic attacks in an animal […]